Ad
CHMA - Chiasma Stock Trading
About | Chiasma Inc. (NASDAQ:CHMA)
Not available
Quote | Chiasma Inc. (NASDAQ:CHMA)
| Last: | $3.76 |
|---|---|
| Change Percent: | -6.0% |
| Open: | $4.08 |
| Close: | $3.76 |
| High: | $4.1 |
| Low: | $3.76 |
| Volume: | 8,189,439 |
| Last Trade Date Time: | 08/05/2021 04:41:57 am |
News | Chiasma Inc. (NASDAQ:CHMA)
-
Six multi-billion dollar deals announced last week. VICI Properties acquires MGM Growth Properties for $17.2 billion. Veoneer receives a superior bid from Qualcomm. For further details see: Merger Arbitrage Mondays - Veoneer Receives A Superior Bid From Qualcomm
-
19 new deals announced in the month of July. Thoma Bravo acquires Medallia. Aon and Willis Towers Watson terminated their business combination agreement. For further details see: Merger Arbitrage Mondays - Thoma Bravo Announces 2 Large Deals In A Single Month ...
Message Board Posts | Chiasma Inc. (NASDAQ:CHMA)
| Subject | By | Source | When |
|---|---|---|---|
| whytestocks: $CHMA News Article - Chiasma to Present Encore and New Data from MPOWERED(TM) Phase 3 T | whytestocks | investorshangout | 05/20/2021 8:40:50 PM |
| * * $CHMA Video Chart 05-05-2021 * * | ClayTrader | investorshub | 05/05/2021 8:39:10 PM |
| whytestocks: $CHMA News Article - Chiasma Merger Investigation: Halper Sadeh LLP Announces Investiga | whytestocks | investorshangout | 05/05/2021 3:55:47 PM |
| Fool was right! | swampboots | investorshub | 05/05/2021 3:50:12 PM |
| whytestocks: $CHMA News Article - Chiasma Reports First Quarter Financial Results and Announced Agre | whytestocks | investorshangout | 05/05/2021 2:15:49 PM |
Ad
-
Pulmatrix appoints Director Anand Varadan PR Newswire LEXINGTON, Mass. , July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and...
-
NEEDHAM, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives ...
-
NEEDHAM, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”) today presented patient-reported outcomes (PROs) data from its MPOWERED™ Phase 3 trial demonstrating that study patients with acromegaly reported si...